JACC: CardioOncology : Impact Factor & More
eISSN: 2666-0873pISSN: 2666-0873
Open AccessShare this on:
Key Metrics
CiteScore 
4.5
Eigenfactor
< 0.001
Impact Factor
10 - 15
SJR
Q3Oncology
SNIP
1.12
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JACC: CardioOncology
JACC: CardioOncology Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 2500 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | American College of Cardiology |
| Frequency | Quarterly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors |
View less
Planning to publish in JACC: CardioOncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JACC: CardioOncology
REPLY: Next Steps for Studying Behaviorally Designed Gamification to Increase Physical Activity.
- 1 Apr 2026
- JACC. CardioOncology
Editorial Board
- 1 Apr 2026
- JACC: CardioOncology
PD-L1 in ICI Myocarditis: When the Immune Brake Fails.
- 1 Apr 2026
- JACC. CardioOncology
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All.
- 1 Apr 2026
- JACC. CardioOncology
REPLY: Next Steps for Studying Behaviorally Designed Gamification to Increase Physical Activity.
- 1 Apr 2026
- JACC. CardioOncology
Editorial Board
- 1 Apr 2026
- JACC: CardioOncology
PD-L1 in ICI Myocarditis: When the Immune Brake Fails.
- 1 Apr 2026
- JACC. CardioOncology
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy.
- 1 Apr 2026
- JACC. CardioOncology
Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All.
- 1 Apr 2026
- JACC. CardioOncology
FAQs on JACC: CardioOncology
How long has JACC: CardioOncology been actively publishing? 
What is the publishing frequency of JACC: CardioOncology?
How many articles did JACC: CardioOncology publish last year?
What is the eISSN & pISSN for JACC: CardioOncology?
What is Citescore for JACC: CardioOncology?
What is SNIP score for JACC: CardioOncology?
What is the SJR for JACC: CardioOncology?
Who is the publisher of JACC: CardioOncology?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations